Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
8-K
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
18 Apr 24
S-8
Registration of securities for employees
26 Feb 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
13 Dec 23
8-K
Entry into a Material Definitive Agreement
3 Nov 23
S-3ASR
Automatic shelf registration
3 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2 Nov 23
8-K
Entry into a Material Definitive Agreement
3 Oct 23
8-K
Departure of Directors or Certain Officers
20 Sep 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
8-K
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
3 Aug 23
8-K
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
23 May 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4 May 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
DEFA14A
Additional proxy soliciting materials
7 Apr 23
DEF 14A
Definitive proxy
7 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
8 Mar 23
S-8
Registration of securities for employees
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 23
8-K
Other Events
22 Feb 23
8-K
Departure of Directors or Certain Officers
16 Feb 23
8-K
Entry into a Material Definitive Agreement
13 Feb 23
8-K
Departure of Directors or Certain Officers
25 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
3 Nov 22
8-K
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
4 Oct 22
8-K
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
9 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Other Events
4 Aug 22
8-K
Departure of Directors or Certain Officers
14 Jul 22
Latest ownership filings
4
Backer Marianne De
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
ANN M. HANLY
2 Apr 24
4
Sung Lee
28 Mar 24
4
ANN M. HANLY
26 Feb 24
4
Backer Marianne De
26 Feb 24
4
Sung Lee
26 Feb 24
4
Phillip Pang
26 Feb 24
4
GEORGE A SCANGOS
26 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
4
GEORGE A SCANGOS
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
4
Phillip Pang
16 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
SB INVESTMENT ADVISERS (UK) LTD
13 Feb 24
SC 13G
STATE STREET CORP
24 Jan 24
SC 13G/A
BlackRock Inc.
23 Jan 24
4
Phillip Pang
3 Jan 24
4
ROBERT J MORE
20 Oct 23
4
GEORGE A SCANGOS
18 Oct 23
4
GEORGE A SCANGOS
18 Sep 23
4
Change in insider ownership
5 Jul 23
4
VICKI L SATO
3 Jul 23
4
Change in insider ownership
30 Jun 23
144
Notice of proposed sale of securities
30 Jun 23
144
Notice of proposed sale of securities
29 Jun 23
4
Change in insider ownership
22 Jun 23
4
Change in insider ownership
20 Jun 23
4
Change in insider ownership
15 Jun 23
4
Phillip Pang
8 Jun 23
144
Notice of proposed sale of securities
7 Jun 23
4
Change in insider ownership
6 Jun 23
144
Notice of proposed sale of securities
5 Jun 23
4
Steven J. Rice
2 Jun 23
4
Saira Ramasastry
2 Jun 23
144
Notice of proposed sale of securities
1 Jun 23
144
Notice of proposed sale of securities
1 Jun 23
4
Change in insider ownership
25 May 23
4
ROBERT NELSEN
24 May 23